MedTrace Logo

Trifecta and Epic ViV Detailed Insights Into Management Strategies and Outcomes

NCT05389631 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 76

Last updated 2024-10-09

No results posted yet for this study

Summary

Non-randomized, open label, non-interventional, multicenter registry to describe risk factors, management strategies, and clinical outcomes in patients undergoing Valve in Valve (ViV) transcatheter aortic valve implantation (TAVI) in a previously implanted Trifecta or Epic valve using retrospective registry data from large volume centers

Conditions

  • Aortic Valve Disease

Interventions

OTHER

no intervention

no intervention

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Helios Health Institute GmbH

    lead OTHER

Principal Investigators

  • Michael Borger, MD, PhD · Leipzig Heart Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-17
Primary Completion
2023-12-21
Completion
2023-12-21

Countries

  • Belgium
  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05389631 on ClinicalTrials.gov